Myasthenia gravis overview

Revision as of 18:49, 28 November 2018 by Fahimeh Shojaei (talk | contribs)
Jump to navigation Jump to search
https://https://www.youtube.com/watch?v=bYGxGdu9MsQ%7C350}}

Myasthenia gravis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Myasthenia Gravis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myasthenia gravis overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myasthenia gravis overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myasthenia gravis overview

CDC on Myasthenia gravis overview

Myasthenia gravis overview in the news

Blogs on Myasthenia gravis overview

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Myasthenia gravis overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Myasthenia gravis (literally "serious muscle-weakness"; from Greek μύς "muscle", Template:Polytonic "weakness", and Latin gravis "serious"; abbreviated MG) is a neuromuscular disease leading to fluctuating muscle weakness and fatiguability. It is an autoimmune disorder, in which weakness is caused by circulating antibodies that block acetylcholine receptors at the post-synaptic neuromuscular junction,[1] inhibiting the stimulative effect of the neurotransmitter acetylcholine. Myasthenia is treated medically with cholinesterase inhibitors or immunosuppressants and in selected cases with thymectomy. At 200-400 cases per million it is one of the less common autoimmune disorders.[1]

Historical Perspective

The first possible patient with Myasthenia gravis, Openchancanough was first described by Virginian Chroniclers in 1664. His symptoms included fatigue, heavy eyelids and weak muscle tone. In the late 1800s the name Myasthenia gravis was created and the classic symptoms of the disease were described. The autoimmune nature of this disease was first described by Simpson and Nastuck in 1959-1960. The first important step in treatment of MG occurred in 1934 by Marry Walker. She observed that the symptoms of patients with myasthenia gravis in similar to those with curare poisoning so their symptoms can improve by a cholinesterase inhibitor like physostigmine. In 1937 Blalock described an improvement in his patient after removal of the thymus and established thymectomy as one of the treatment options of MG. In 1970s the use of immunosuppressants, azathioprine and plasma exchange became more prevalent.

Classification

Myasthenia gravis may be classified into 4 sub types based on presence of autoantibodies: Pure ocular form, generalized form with anti-AChR antibodies, the forms without classical anti-AChR antibodies, neonatal MG, congenital.

Pathophysiology

Myasthenia gravis is a neuromuscular disease caused by an autoimmune reactions. The main problem in this disease is the abnormal transmission of nerve impulses to muscle fibers in NMJ. Genes involved in the pathogenesis of Myasthenia gravis include: The Major Histocompatibility Complex, the CHRNA1 Locus, the PTPN22 Gene, the FCGR2 Locus and the CTLA4 Locus.

Causes

Myasthenia gravis may be caused by thymus abnormalities, genetic and environment.

Differentiating Myasthenia Gravis from other Diseases

Differential diagnosis for Myasthenia gravis includes: Adult Botulism, infant Botulism, guillian-Barre syndrome, eaton lambert syndrome, electrolyte disturbance, organophosphate poisoning, tick paralysis, tetrodotoxin poisoning, stroke, poliomyelitis, transverse myelitis, neurosyphilis, muscular dystrophy, multiple sclerosis, amyotrophic lateral sclerosisand myositis.

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Surgery

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

References

  1. 1.0 1.1 Conti-Fine BM, Milani M, Kaminski HJ (2006). "Myasthenia gravis: past, present, and future". J. Clin. Invest. 116 (11): 2843–54. doi:10.1172/JCI29894. PMID 17080188. PMC 1626141

Template:WH Template:WS